



Living Cell Technologies Limited

Company Announcement

Living Cell Technologies' Paper Selected for "Best Publications of 2009" by Journal of Neural Engineering

13 April 2010: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of cell implants, is pleased to announce that its publication on the use of encapsulated choroid plexus cells has been highlighted as one of the best articles published by the *Journal of Neural Engineering* in 2009. It is included in a collection that the publisher has made accessible free to read until 31 December 2010 at <http://herald.iop.org/jnehighlights/m320/zea/319831/link/3322>.

The Journal selected the articles for inclusion in the Collection on the basis of having received the highest praise from international referees and the greatest numbers of downloads from the Journal's website.


In October 2009, the journal published LCT's paper titled "*Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma*" which shows that long-lasting therapeutic implants of NTCELL may be used to treat brain disease. NTCELL comprises encapsulated porcine cells of the choroid plexus of the brain. The cells release growth factors and neurotrophins, which are a range of agents that protect and maintain the health of brain cells. NTCELL was designed to protect brain cells from disease and injury and to enhance the natural repair mechanisms in the brain.

The porcine choroid plexus cells are encapsulated in a seaweed-derived gel. The encapsulation protects the cells from rejection by the immune system allowing implantation without the need for toxic anti-rejection drugs. The publication reports new experimental data indicating that the choroid plexus cells release neuroprotective agents including antioxidants and growth supporting factors.

The implanted cells were still alive when retrieved 6 months after implantation into the brain in animals. The report adds to LCT's previously published and presented data on the beneficial effects of NTCELL implants in animal models of Parkinson's disease, Huntington's disease, stroke and hearing loss caused by degeneration of the auditory nerve.

Reference: Skinner SJM, Geaney MS, Lin H, Muzina M, Anal AK, Elliott RB, Tan PLJ. Encapsulated living choroid plexus cells: potential long-term treatments for central nervous system disease and trauma *Journal of Neural Engineering*. <http://herald.iop.org/jnehighlights/m320/zea/319831/link/3322>

- Ends -



Photos show the choroid plexus of the brain and encapsulated choroid plexus cells.

For further information: www.lctglobal.com

At the company:

Dr. Paul Tan
Chief Executive Officer
Mob: 021 608 784 (NZ)
Tel: +64 9 276 2690
ptan@lctglobal.com

Mr John Cowan
Finance & Administration Manager
Tel: +64 9 276 2690
jcowan@lctglobal.com

Prof. Bob Elliott
Medical Director
Mob: +64 27 292 4177
Tel: +64 9 276 2690
belliott@lctglobal.com

Media and investor enquiries:

International enquiries:
College Hill - lct@collegehill.com

US: Erik Clausen / Rebecca Skye Dietrich
Mob: +1 781 608 7091
Tel: +1 415 230 5385

Europe: Sue Charles / Justine Lamond
Mob: +44 7968 726585
Tel: +44_20 7457 2020

NZ and Australia:
Buchan Consulting
Paul Dekkers
Tel: +612 9237 2800
pdekkers@bcg.com.au

About Living Cell Technologies - www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a bio-certified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressant drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will", "project", "believe", "forecast",



“expected”, “estimated”, “targeting”, “aiming”, “set to”, “potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s and other health authorities’ requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.